Every Form 4 that Avita Medical, Inc. (RCEL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RCEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RCEL filings page.
AVITA Medical, Inc. (RCEL) officer David D. O'Toole, the CFO, reported an amended insider transaction. On June 12, 2026, he purchased 2,000 shares of AVITA Medical common stock at $3.97 per share in an open market or private transaction. This amendment corrects the original filing’s transaction code from “A” to “P”. Following the purchase, his directly held position is 152,927 shares, which includes unvested RSUs.
O'Toole David D reported acquisition or exercise transactions in this Form 4 filing.
AVITA Medical CFO David D. O'Toole received a grant of 2,000 shares of common stock at a reference value of $3.97 per share. This was a compensation-related award, not an open-market purchase, and increased his directly held stake to 152,927 shares, including unvested RSUs.
AVITA Medical, Inc. director Woody Joseph Fralin made an open-market purchase of the company’s common stock. On June 9, 2026, he bought 5,200 shares at $4.00 per share, bringing his direct holdings to 107,961 shares, which the disclosure notes include unvested RSUs.
AVITA Medical, Inc. director Woody Joseph Fralin reported buying a total of 10,000 shares of common stock in open-market transactions. The purchases occurred at prices of $4.18 and $4.20 per share. A footnote indicates the reported holdings include unvested restricted stock units (RSUs).
AVITA Medical, Inc. director Woody Joseph Fralin reported buying a total of 10,000 shares of the company’s Common Stock in open-market transactions. The purchases on June 3, 2026 were made at prices of $4.0899 and $4.0999 per share.
After these trades, Fralin directly holds 92,761 shares of AVITA Medical common stock, which the disclosure notes includes unvested restricted stock units (RSUs). These are straightforward open-market purchases, increasing his direct equity stake in the company.
AVITA Medical, Inc. director Robert McNamara reported receiving new equity compensation. He was granted 22,214 restricted stock units, each representing one share of common stock, subject to time-based vesting. These RSUs vest 12 months after the January 20, 2026 grant date, following stockholder approval obtained on June 3, 2026.
McNamara was also granted 16,133 stock options to buy common stock at an exercise price of $3.77 per share. The options were approved by the board on January 5, 2026, have a grant date of January 20, 2026, become exercisable starting January 20, 2027, and expire on January 20, 2036. Following these awards, he directly owns 108,985 shares of common stock, including unvested RSUs.
AVITA Medical, Inc. granted equity awards to director Woody Joseph Fralin. On January 5, 2026, he received 40,547 restricted stock units (RSUs) and 29,446 stock options with a $3.47 exercise price, subject to stockholder approval obtained on June 3, 2026. On January 20, 2026, he received an additional 22,214 RSUs and 16,133 stock options with a $3.77 exercise price. The RSUs vest over time, and the options vest in three equal annual installments, providing long-term, stock-based compensation. Following these awards, his direct common stock holdings increased to 82,761 shares.
AVITA Medical, Inc. director Michael E. Tarnoff reported equity awards in the form of restricted stock units (RSUs) and stock options. On August 6, 2025, he received 26,250 RSUs and 19,063 stock options with an exercise price of $5.36 per share, vesting in three equal annual installments after the first anniversary. On January 20, 2026, he received an additional 22,214 RSUs that vest 12 months after the grant date and 16,133 stock options with an exercise price of $3.77 per share, also vesting in three equal annual installments beginning one year after grant. These awards were approved by the Board and were subject to stockholder approval obtained on June 3, 2026. Following the most recent RSU grant, Tarnoff directly holds 48,464 shares of common stock.
AVITA Medical, Inc. director Jeremy Curnock Cook reported equity awards consisting of restricted stock units and stock options granted as part of his compensation. He received 22,214 RSUs, each representing one share of common stock, which are subject to time-based vesting 12 months after the January 20, 2026 grant date and were approved by stockholders on June 3, 2026. He also received options to acquire 16,133 shares of common stock at an exercise price of $3.77 per share, exercisable starting January 20, 2027 and expiring January 20, 2036. Following the RSU award, his direct common stock holdings, including unvested RSUs, total 62,050 shares, and he holds 16,133 stock options.
AVITA Medical, Inc. director Suzanne Crowe reported equity awards granted as part of her compensation. She received 22,214 restricted stock units, each representing one share of common stock, which vest 12 months after the January 20, 2026 grant date, subject to previously obtained stockholder approval. She was also granted 16,133 stock options to buy common stock at an exercise price of $3.77 per share, exercisable until January 20, 2036. Following these awards, her direct holdings total 69,148 shares of common stock, which include unvested RSUs and 22,990 CHESS Depositary Interests that translate into 4,598 of these shares.
AVITA Medical, Inc. director Jan Stern Reed reported equity awards consisting of restricted stock units and options. Reed received 22,214 restricted stock units, each representing one share of common stock, that vest 12 months after the January 20, 2026 grant date and were subject to stockholder approval obtained on June 3, 2026.
On the same grant date, Reed was also granted 16,133 stock options to buy 16,133 shares of common stock at an exercise price of $3.77 per share, with an expiration date of January 20, 2036, also approved by stockholders on June 3, 2026. Following the equity award, Reed directly holds 73,225 shares of common stock, including unvested RSUs.
AVITA Medical, Inc. director Woody Joseph Fralin bought a total of 20,000 shares of Common Stock in open-market transactions. The purchases occurred on June 1 and 2 at prices between $4.18 and $4.34 per share, bringing his direct holdings to 20,000 shares.
AVITA Medical, Inc. CFO David D. O'Toole acquired 5,000 shares of common stock in a Form 4 transaction. The shares were obtained through the company’s Employee Share Purchase Plan at $3.0515 per share, based on an 85% discount to the December 1, 2025 closing price. Following this acquisition, he directly holds 150,927 shares, including unvested RSUs.
AVITA Medical, Inc. President and CEO Vance Cary Guy acquired 5,000 shares of common stock through the company’s Employee Share Purchase Plan. The shares were purchased at $3.0515 per share, equal to 85% of the closing price on December 1, 2025, for the ESPP period that ran through May 31, 2026.
After this transaction, he holds 40,771 shares directly, a figure that includes unvested restricted stock units. The acquisition is classified as a grant or award and was exempt under Rule 16b-3(d) and Rule 16b-3(c), indicating a compensation-related, routine purchase rather than an open-market trade.
AVITA Medical, Inc. CFO David D. O'Toole reported an open-market purchase of 2,000 shares of common stock at a price of $4.26 per share. Following this transaction, he directly holds 145,927 shares, which the disclosure states include unvested restricted stock units.
AVITA Medical, Inc. CFO David D. O'Toole reported an open-market purchase of common stock. He bought 2,000 shares at $4.24 per share, increasing his direct holdings to 143,927 shares. The reported total includes unvested restricted stock units, indicating both vested and unvested equity exposure.
AVITA Medical, Inc. Chief Financial Officer David D. O'Toole reported an open-market purchase of 3,000 shares of common stock on February 19, 2026 at $4.15 per share. Following this buy, his directly held stake increased to 140,127 shares, which includes unvested restricted stock units.
AVITA Medical, Inc. CFO David D. O'Toole reported equity compensation awards consisting of stock options and restricted stock units. He acquired 155,510 stock options with an exercise right to buy common shares, and 105,470 shares of common stock in the form of restricted stock units, both at a stated price of $0.00 per share.
The RSUs represent rights to receive one share of common stock each, vesting in three equal annual installments starting 12 months after the February 18, 2026 grant date. The stock options also vest in three equal annual installments beginning on the first anniversary of the same grant date, aligning his compensation with longer-term company performance.
AVITA Medical, Inc. reported that Chief Legal Officer Nicole Kelsey received equity awards consisting of stock options and restricted stock units. She was granted stock options for 145,060 shares at an exercise price of $0.0000 per share and 98,390 shares of Common Stock through restricted stock units.
The restricted stock units each represent the right to receive one share of Common Stock and vest in three equal annual installments beginning 12 months after the February 18, 2026 grant date. The stock options vest in three equal annual installments beginning on the first anniversary of the February 18, 2026 grant date, aligning the awards with multi-year service and performance.